Multivalent vaccines are designed to immunize against two or more pathogens in a single dose vaccination. A challenge for wide spread use of these vaccines is their lower protection efficacy compared to monovalent vaccines that immunize individuals against a single pathogen. We sought, for the first time, to evaluate the outcomes of bivalent and monovalent vaccines in terms of the reduction in the number of infections over time. For this evaluation, we developed epidemiological models governing the transmission dynamics of two immunologically unrelated pathogens, where immunity conferred by vaccination or natural infection of one pathogen does not provide any cross-protection against the other pathogen. We assumed that a monovalent vaccine provides full, but temporary, protection against a particular pathogen. While protecting against both pathogens requires two pathogen-specific monovalent vaccines, a single dose of the bivalent vaccine provides partial protection against both pathogens. We analyzed the two models to investigate the impact of vaccination. In addition to examining global behaviours and disease persistence of the models, we performed simulations to show the existence of a biologically feasible region for the bivalent vaccine to outperform monovalent vaccines for prevention of disease transmission using a lower number of vaccines.
Introduction
Vaccination has proven as the most effective and economical measure against many communicable diseases. [1] [2] [3] The aim of vaccination is to provide active acquired immunity against a particular pathogen, thereby preventing infection and related outcomes upon exposure to the pathogen. Since the discovery of the polysaccharide conjugate vaccines in the late 1980s, 4 the impact of vaccination on the pathogenpopulation landscape has dramatically changed. Haemophilus influenzae serotype b (Hib) is the first infection against which a polysaccharide conjugate vaccine was developed and implemented as part of the infant immunization programs in several affected populations. 4 Since then, a number of multivalent combined or unimolecular vaccines have been produced to protect individuals against different pathogens or different serotypes of a pathogen using a single vaccine dose. [5] [6] [7] A particular example is the DTaP-IPV-Hib combined vaccine that protects individuals against diphtheria, tetanus, pertussis, polio and Hib.
8
Multivalent vaccines have the advantage of providing protection against two or more diseases in a single dose, and therefore eliminate a number of logistical and administrative challenges associated with vaccination using monovalent vaccines. However, the protection efficacy of multivalent vaccines may be lower than that provided by individual monovalent vaccines. For instance, several studies have demonstrated lower immunogenicity to the Hib component of the DTaP-IPV-Hib combined vaccine products that include Hib antigens when compared with individually administered Hib polysaccharide conjugate vaccine.
9-12 In addition to the lower protection efficacy conferred by such multivalent vaccines, waning immunity and deferral of boosting may be a cause for the resurgence of some severe infections, such as invasive Hib disease.
13
In this study, we develop vaccination models to investigate, the effect of monovalent and bivalent vaccines, and compare the outcomes in terms of the vaccine-induced protection and vaccine coverage. We consider these models for two pathogens (referred to as pathogen A and pathogen B), and assume that no crossprotection is conferred through vaccination or natural infection. In the monovalent model, vaccines are assumed to provide full protection against each pathogen for a certain period of time. In the bivalent model, we assume that the vaccine is imperfect, providing only partial protection against each pathogen. While investigating theoretical aspects of these models, we simulate them to illustrate the time profiles of infection spread in the population. By means of simulations, we also show the importance of the durations of vaccine-induced protection and naturally acquired immunity when comparing the outcomes of these models.
Vaccination models
To develop vaccination models, we divide a homogeneously mixing population of size N into classes of susceptibles (S), infected individuals with pathogen A (I A ), infected individuals with pathogen B (I B ), recovered individuals from infection with pathogen A (T A ), recovered individuals from infection with pathogen B (T B ), infected individuals with pathogen B after recovery from infection with pathogen A (J B ), infected individuals with pathogen A after recovery from infection with pathogen B (J A ), and recovered individuals after subsequent infections with both pathogens (R). We assume that recovery from infection with one pathogen does not provide any cross-protection against the other pathogen. We exclude the occurrence of co-infection with both pathogens A and B from our models. Vaccination models include other subpopulations based on the type of vaccine being implemented. In the absence of vaccination, the model (2.3) is expressed as the following system of differential equations Parameters of this system are described in Table 2 .1. This system will be used as a basic framework for the development of monovalent and bivalent vaccination models.
The monovalent vaccine model (MVM)
In this model, susceptible individuals may be vaccinated against pathogen A (W A ) only, pathogen (W B ) only, or both pathogen (W AB ). Vaccination against each pathogen is assumed to provide full protection for a certain period of time. After the vaccine-induced protection has waned, individuals will become susceptible to the infection again. We assume that the durations of vaccine-induced protection and naturally acquired immunity (through natural infection) are the same for both pathogens A and B. Considering the basic framework in (2.1), the MVM is expressed by
where
In this model, X A represents the class of individuals who are infected with pathogen A after being vaccinated only against pathogen B. Similarly, X B represents the class of individuals who are infected with pathogen B after being vaccinated only against pathogen A. The overall vaccination coverage is given by p m (where 0 ≤ p m ≤ 1). The parameters r A , r B , and r AB represent respectively the fractions of this coverage considered for vaccination against pathogen A, against pathogen B, and against both pathogens, giving r A + r B + r AB = 1. Other parameters of this model are described in Table 2 .1.
The bivalent vaccination model (BVM)
In this model, we assume that a single dose of the vaccine provides protection against both pathogens A and B. In contract to the monovalent vaccine, we assume that the bivalent vaccine confers only partial protection against each pathogen, which reduces susceptibility to infection. Therefore, vaccinated individuals (V AB ) may encounter infection with pathogen A or pathogen B at reduced transmission rates. Recovered individuals from infection with pathogen A (Q A ) and pathogen B (Q B ) following vaccination may respectively acquire infection with pathogen B (Y B ) and pathogen A (Y A ). Inclusion of these subpopulations to the basic framework gives the following system of differential equations:
In this model, p b represents the vaccination coverage with 0 ≤ p b ≤ 1. Other parameters are described in Table 2 .1.
Analysis of the MVM
The system is at an equilibrium if the time derivatives of its variables are zero. The equation
describes the dynamics of the total population. At the equilibrium for the total population we have N * = Λ/d, which is globally attracting. From the system specifications, it follows that nonnegative initial values give rise to nonnegative solutions. It is thus meaningful to define the phase space Γ for model (2.3), as
The space Γ is positively invariant with respect to the model (2.3). The solutions are bounded, and remain nonnegative for nonnegative initial values. There is a unique disease-free equilibrium (DFE) given by
3)
The disease-free subspace is defined as
In Γ 0 , model (2.3) reduces to a linear system, and it is easy to obtain that the DFE is globally asymptotically stable in the disease-free subspace Γ 0 .
We define the corresponding reproduction numbers for pathogens A and B in model (2.3), as we introduce an individual infected with pathogen A or B, into a completely susceptible population: A Proof of the theorem is provided in Appendix A. We performed theoretical analysis to investigate the local and global dynamics of the MVM. In particular, after establishing the existence of a unique DFE and describing its local stability, the existence of endemic equilibria are also investigated. Various threshold quantitiesreproduction numbers-are defined to describe local and global stability, and we give sufficient conditions for disease persistence in the MVM. These analyses provide rich dynamics of the model, and we refer the reader to Appendix A for their derivations and proofs.
Analysis of the BVM
The steady state N * = Λ/d for the total population is globally attracting in model (2.5). Furthermore, nonnegative initial conditions give rise to nonnegative solutions. The phase space for model (2.5) is defined as
where for simplicity we use the same notation as for model (2.3). The space Γ is positively invariant with respect to model (2.5). The solutions are bounded, and remain nonnegative for nonnegative initial values.
There is a unique DFE given by
In the disease-free subspace Γ 0 = {x ∈ Γ :
the DFE is globally asymptotically stable in model (2.5). We define the reproduction numbers for pathogens A and B as: The proof of this theorem is similar to Theorem 3.1, and we omit it. One can also show the persistence of the disease, and investigate the local and global behaviour of the BVM. Details of such dynamics are provided in Appendix B. Proofs and detailed explanations are omitted where they are similar to those obtained for the MVM.
Simulation results
The theoretical analyses of the MVM and BVM (see Appendices A and B) provide rich dynamics of these systems with respect to their local and global behaviours.
The purpose of our simulations here is to compare these models to determine the conditions under which a bivalent vaccine could outcompete monovalent vaccines in preventing infection spread by both pathogens. This comparison is associated with two key parameters including the level of vaccine-induced protection and vaccination coverage of individuals in the population. In the BVM, the number of vaccines is the same as the vaccination coverage; however, in the MVM, protecting individuals against both pathogens with the same coverage as in the BVM requires twice as many vaccinations.
In the MVM, the number of individuals vaccinated per unit time is p m Λ. A fraction r A + r B of vaccinated newborns receives vaccine against one pathogen only, and the remaining fraction r AB receives vaccines against both pathogens A and B. Since r A + r B + r AB = 1, the total number of vaccines administered per unit time is (r A + r B ) p m Λ + 2 r AB p m Λ = p m Λ(1 + r AB ). In the BVM, the number of newborns vaccinated per unit time is p b Λ, and each vaccinee receives a single dose of vaccine against both pathogens. Hence, the total number of vaccines is p b Λ. It is therefore meaningful to compare the total vaccine doses (1 + r AB ) p m Λ and p b Λ per unit time in the two models. We performed numerical simulations to reveal whether it is possible to reduce the incidence of infections through a bivalent vaccine without increasing the total number of vaccines in the population compared with the MVM.
Heatmaps presented in Figure 1 show the difference in the cumulative number of infections for each pathogen in the two models over twenty years following the start of vaccination. The simulations were run when p m and p b vary in their respective ranges between 0 (in the absence of vaccination) and 1 (full vaccination coverage of newborns). In our simulations, four values were considered for the average time period of protection following vaccination or recovery from infection. Figure 1 shows the results for lifetime protection, i.e., θ = 0 (A,E); θ −1 = 5 years (B,F); θ −1 = 10 years (C,G); and θ −1 = 15 years (D,H) protection. Other parameter values are provided in Table 2 .1. First and second rows in Figure 1 correspond to the difference in the cumulative number of infections between the two models for pathogens A and B, respectively, with the magnitude of difference indicated by colour bars. The red line indicates the same cumulative number of infections in the two models. The black dashed-line corresponds to the same number of vaccine doses in both models (i.e., p b = (1 + r AB )p m ). Colours corresponding to positive numbers above the red line identify the areas in the heatmaps where the cumulative number of infections in the MVM is higher than that in the BVM. Any point below the black dashed-line corresponds to a lower vaccine doses in the BVM compared with the MVM (that is, p b < p m (1 + r AB )). We observed that the red line is below the black dashed-line for values of θ (inverse of the duration of protection) used for simulations, implying that it is possible to reduce the cumulative number of infections for each pathogen by implementing a bivalent vaccine while using a lower number of vaccines compared to the MVM. However, as the length of the duration of protection following vaccination or recovery from natural infection increases, the difference in the cumulative number of infections between the two vaccination models decreases. Table 2 .1.
For comparison purposes, we also simulated the time profiles of infection caused by each pathogen in the two models. For these simulations we fixed a pair of (p m , p b ) in the area between the red and black dashed lines in the heatmaps. Figures 2 and 3 show these time profiles, where red, blue, and green curves correspond to the classes I A , J A , and X A in each model, and magenta curves in Figure 3 correspond to the class Y A in the BVM. Parameter values are provided in Table 2 .1 with p m = 0.6 and p b = 0.8. These simulations show a similar qualitative behaviour of infection curves when the difference in the cumulative number of infections between the two models is small. However, for large differences ( Figure 1C ), the corresponding infection curves render different long-term behaviour (Figures 2-C,G and 3-C,G) .
Remark. For the simulations presented here, we assumed the same duration of immune protection following vaccination and recovery from natural infection. However, for many diseases, natural infection may induce stronger and longer-lasting immunity than vaccination. We therefore carried out further simulations with a longer protection period for immunity induced by natural infection compared to that conferred by vaccination. We observed (Figure 4 ) that the effect of naturally acquired immunity transcends the effect of vaccine-induced immunity. 
Discussion
Bivalent vaccines have the advantage of providing immunity against two or more pathogens in a single-dose vaccination. These vaccines can potentially reduce costs associated with the administration of single-dose vaccines for different diseases, in addition to providing the uniform vaccination coverage of each disease. However, the protection efficacy of such vaccines may not be as good as that provided by individually administered monovalent vaccines against different pathogens. A number of bivalent vaccines are currently being used in many countries, [5] [6] [7] [8] however an important question is whether these vaccines could reduce the morbidity caused by different pathogens in the population without increasing vaccine doses compared to monovalent vaccines.
To address this question, we developed, for the first time, epidemiological models for transmission dynamics of two immunologically unrelated pathogens, where immunity conferred by vaccination or natural infection of one pathogen does not provide any cross-protection against the other pathogen. These models have the same basic framework in the absence of vaccination, but they are structurally different when monovalent and bivalent vaccines are incorporated. We carried out the theoretical analysis to show global behaviours and persistence. While the vaccineinduced immunity wanes over time in both models, our main assumption is that monovalent vaccines provide full protection against each pathogen, but the bivalent vaccine provides only partial protection against both pathogens.
We compared the outcomes of vaccination in each model by means of numerical simulations. For this evaluation, we considered the cumulative number of infections caused by each pathogen in the two models overtime, while changing the time duration of the vaccine-induced protection. Our simulation results (Figure 1) suggest that, within biologically feasible range of model parameters, it is possible to reduce the total number of infections using a bivalent vaccine with a lower number of vaccines compared to the MVM. This is illustrated by the region between red and dashed-black lines in Figure 1 . We observed that the reduction in the total number of infections over a certain period of time depends significantly on the duration of the vaccine-induced protection (i.e., the parameter 1/θ). We also note that our results are quantitatively subject to variations in the parameter space; however, we expect that qualitative signatures of the models remain intact in epidemiologically feasible spectra.
In models considered here, we assumed no cross-protection between the two pathogens. When considering bivalent vaccines for different strains of the same pathogen in the presence of cross-protection, the dynamics of disease spread and prevention become more complex. In this case, recovery from infection with one strain may provide partial protection against infection with another strain. Complexity of disease dynamics when using this type of bivalent vaccines merits further investigation. Additional study of the frameworks developed here for specific vaccines and scenarios is proceeding.
Let s(J) denote the maximum real part of the eigenvalues of J. For stability of the DFE, we require s(J) < 0. It follows from the block diagonal structure of J that the six eigenvalues of the matrix arise pairwise as the eigenvalues of the diagonal blocks, which are
We note that λ 2 , λ 3 , λ 5 , λ 6 < 0; moreover λ 1 < 0 (> 0) if and only if R Am < 1 (> 1), and λ 4 < 0 (> 0) if and only if R Bm < 1 (> 1). These imply the local stability of the DFE.
We define four subspaces as follows: 
where we usedŜ +V +Î +R = N , F B ≡ 0, and
0 , the reproduction number of system (A.6) is calculated as
and using r A + r AB = 1 − r B we note that this formula is the same as that of R Am in (3.5). Hence, R Am can be used to describe the reproduction number of system (A.6). The system (A.6) gives a special case of the system (2) in Ref. 14. Therefore, R Am gives the reproduction number associated with the system (2) in Ref. 14. Following the analysis in Ref. 14, we definê
Theorem Appendix A.1 Consider the system (A.6). There is a unique endemic equilibriumÊ 1 if and only if R Am > 1. The endemic equilibriumÊ 1 is globally asymptotically stable in the subspaceD 1 \D 0 whenever R Am > 1. For any R Am ≥ 0 there is a unique DFE, denoted byÊ 0 , which is globally asymptotically stable inD 1 whenever R Am ≤ 1.
Proof. We recall from the equation (3.1) that there is a unique equilibrium N * for the total population, hence every equilibrium of (A.6) lies inD 1 . It follows from the non-negativity of solutions thatD 1 is invariant with respect to (A.6). The dynamics of system (A.6) restricted toD 1 is equivalent to that of system (15) in Ref. 14. Using Theorems 1, 3, and 4, and Lemmas 3 and 5 of Ref. 14, we establish the assertion of the theorem.
It is worth mentioning that system (2) in Ref. 14 allows for the forward and backward bifurcations at the DFE. However, the analysis of system (2) in Ref. 14 shows that the backward bifurcation is impossible with a fully protective vaccine, which excludes the possibility of a backward bifurcation in our system (A.6).
For system (A.6), we obtained thatŜ,V ,Î, andR converge to one of the two attractorsÊ 0 andÊ 1 
A.2. Persistence and global behavior
We recall from the equation (3.1) that the total population converges to the equilibrium N * . We consider model (2.3) as a non-autonomous system with nonautonomous term N (t), which is governed by (3.1). By lim t→∞ N (t) = N * , model (2.3) is asymptotically autonomous with the limiting system which arises from (2.3) by replacing N (t) with N * . In this section our analysis is restricted to the case when the total population is at its steady state, that is, N = N * . By the theory of asymptotically autonomous systems (see Refs. 15-17) the dynamics of the limiting system is qualitatively equivalent to that of the original model (2.3).
Note that the equation for W AB in model (2.3) is independent from other equations, and
We define the quantities
Note that R Am ≤ R 
In the subspace Γ W , we have
The derivativeV 1 ≤ 0 if R Similarly, when R c Bm ≤ 1 and R Am ≤ 1, we obtain for V 2 (x) = I B + J B + X B thatV 2 ≤ 0. Moreover the largest invariant set in V 2 = 0 is the DFE. Thus, in both cases, the limit set of each solution is the DFE, which proves the theorem. 
where S * , T * . Furthermore, at any equilibrium, the total population is at the steady state N * , and we obtain
Equating the right hand sides of the equations in model (2.3) to zero, it is easy to see that
; thus we derive from the above equation that
/N * , from the ninth equation of (2.3), we obtain
where for the last equality we used (I *
and R * Bm < R Bm . The relation R * Am < R Am can be proven similarly.
We now recall some definitions and results from Ref. 18.
Definition Appendix A.1 Let X be an arbitrary nonempty set and ρ : X → R + .
A semiflow Φ : R + × X → X is called uniformly weakly ρ-persistent, if there exists some > 0 such that
Φ is called uniformly (strongly) ρ-persistent, if there exists some > 0 such that
A set M in X is called uniformly weakly ρ-repelling if there is no x ∈ X such that ρ(x) > 0 and Φ(t, x) → M as t → ∞.
Uniformly weakly ρ-persistence is a property that is weaker than uniformly (strongly) ρ-persistence. However, Theorem 4.5 in Ref. 18 establishes conditions on X and Φ such that uniformly weakly ρ-persistence implies uniformly (strongly) ρ-persistence.
In what follows, we present uniformly persistence results for model (2.3). It is easy to see that the model generates a continuous flow on the phase space. After showing weakly persistence for some choices of ρ, we will consider the conditions of Theorem 4.5 in Ref. 18 to prove uniformly (strongly) persistence. We will also use Theorem 8.17 in Ref. 18 to assert uniformly weakly ρ-persistence, by examining some uniformly weakly ρ-repelling sets.
The ω-limit set of a point x ∈ X is defined as ω(x) = {y ∈ X : ∃{t n } n≥1 such that t n → ∞, Φ(t n , x) → y as n → ∞} .
Proof. We prove the theorem for the persistence of pathogen A only. The phase space Γ is nonempty, so let X = Γ and x = (S, I A , . . . , R) ∈ Γ be any state of the model. Consider ρ(x) = I A + J A + X A . Then we have {x ∈ Γ : ρ(x) = 0} = Υ A , the extinction space of pathogen A. We investigate Ω := ∪ x∈Υ A ω(x). From Theorem Appendix A.2, it follows that Ω = M 1 ∪ M 2 whenever R Bm > 1, and Ω = M 1 whenever R Bm ≤ 1, where M 1 is the DFE and
First, we show that M 1 is uniformly weakly ρ-repelling if R Am > 1. Suppose there is some x such that ρ(x) > 0 and Φ(t, x) → M 1 as t → ∞; that is, there is a solution such that
. Thus, for any > 0 and sufficiently large t > 0, we have
− . For the derivative of I A + J A + X A , we obtain
which is positive for small by R Am > 1, contradicting lim t→∞ (I A (t) + J A (t) + X A (t)) = 0. Note that this result holds when R *
We derive similarly that M 2 is uniformly weakly ρ-repelling if R * Am > 1. Assume the contrary, there is a solution such that I A (t) + J A (t) + X A (t) > 0 but lim t→∞ (I A (t) + J A (t) + X A (t)) = 0 and lim t→∞ (S(t) + W B (t) + T B (t)) = S * + W * Proof. For X = Γ and x = (S, I A , . . . , R) ∈ Γ, we consider ρ(x) = I A + J A + X A + I B + J B + X B . Then, the disease-free subspace is {x ∈ Γ : ρ(x) = 0} = {(S, I A , . . . , R) :
In the absence of both pathogens, the system is linear and the DFE is globally asymptotically stable. Let Ω := M 1 where M 1 is the DFE. We show that M 1 is uniformly weakly ρ-repelling if R Am > 1 and R Bm > 1. Suppose there exists a solution such that I A (t) + J A (t) + X A (t) > 0 and I B (t) + J B (t) + X B (t) > 0 but lim t→∞ (I A (t)+J A (t)+X A (t)+I B (t)+J B (t)+X B (t)) = 0 and lim t→∞ (S(t)+W B (t)+
. Then, for any > 0 and sufficiently large t > 0, we have
which is positive for small since R Am > 1 and R Bm > 1, contradicting lim t→∞ (I A (t) + J A (t) + X A (t) + I B (t) + J B (t) + X B (t)) = 0.
We apply Theorem 8.17 in Ref. 18 to derive that I A + X A + I B + X B is weakly ρ-persistent. We note that Ω ⊂ M 1 , M 1 is isolated, compact, invariant, acyclic, and weakly ρ-repelling. The phase space X is compact, and hence there exists a compact attractor. Furthermore, the flow is continuous, and thus 
It is easy to see that all four subspaces are invariant with respect to model (2.5) .
We investigate the model (2.5) in the special case where one of the pathogens (say, without loss of generality, pathogen B) is absent. The analysis in this subsection is therefore restricted to the subspace Υ B . For the special case where pathogen A is absent, one can obtain similar results to those presented here. 
where we usedS +V +Ȋ +Ȓ = N and
0 , the reproduction number of (B.2) is calculated as
and we note that this formula is the same as that of R Ab in (4.3). Hence, R Ab can be used to describe the reproduction number of system (B.2). The system (B.2) gives a special case of system (2) in Ref. 14. Thus, R Ab gives the reproduction number associated with system (2) in Ref. 14. Following the analysis of Ref. 14, we definȇ
The following results are obtained by similar arguments as those in Theorem Appendix A.1. The equilibrium associated withȆ 0 is therefore a disease-free equilibrium in model (2.5), and by uniqueness it follows that it is the DFE. At the equilibrium of model (2.5) that is associated withȆ 1 , it follows that I * A , X * A > 0. We denote this equilibrium by E A b , which is an endemic equilibrium with respect to pathogen A and disease-free with respect to pathogen B. We refer to E A b as the boundary endemic equilibrium of model (2.5) in the presence of pathogen A and in the absence of pathogen B. With the above arguments, we have proven the first part of the theorem, and the second part can be shown similarly.
B.2. Persistence
Here, we show sufficient conditions for the persistence of the disease in model (2.5). We again define the reproduction number R * Ab ( R * Bb ), when the population is at its steady state E Recall that pathogen B is absent at both equilibria. Equating the right hand sides of the equations for Q A , V AB , and X A in model (2.5) to zero, we obtain
Using these equalities, we derive
Since the total population is at the steady state N * at any equilibrium, we obtain 
